Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression

Journal of Psychopharmacology

Volumn 27, Issue 10, 2013, Pages 894-902

  Nugent, Allison C ^a   Carlson, Paul J ^b   Bain, Earle E ^c   Eckelman, William ^d   Herscovitch, Peter ^e   Manji, Husseini ^f   Zarate, Carlos A ^a   Drevets, Wayne C ^f,g,h  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f JOHNSON AND JOHNSON   (United States)

^g LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

^h University of Oklahoma Tulsa College of Medicine   (United States)

Author keywords

bipolar disorder; lithium; Positron emission tomography; serotonin type 1A receptor; valproic acid

Indexed keywords

4 FLUORO N [2 [4 (METHOXYPHENYL)PIPERAZINO]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE F 18; LITHIUM; MOOD STABILIZER; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BINDING AFFINITY; BIPOLAR DEPRESSION; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HIPPOCAMPUS; HUMAN; MALE; MOOD; NEUROIMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING;

BIPOLAR DISORDER; LITHIUM; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN TYPE 1A RECEPTOR; VALPROIC ACID;

ADULT; AMYGDALA; BIPOLAR DISORDER; FEMALE; FUNCTIONAL NEUROIMAGING; HIPPOCAMPUS; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1A; VALPROIC ACID; YOUNG ADULT;

EID: 84883858897     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113499204     Document Type: Article

References (73)

1. Diagnostic and Statistical Manual of Mental Disorders: Fourth Edition, Text Revision DSM-IV-TR. Washington, DC: American Psychiatric Association ; 2000 :
2. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002 ; 159: 1-50
3. Bauer M, Adli M, Bschor T, et al. Lithium's emerging role in the treatment of refractory major depressive episodes: Augmentation of antidepressants. Neuropsychobiology. 2010 ; 62: 36-42
4. Birkenhager TK, van den Broek WW, Fekkes D, et al. Lithium addition in antidepressant-resistant depression: Effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration. Prog Neuropsychopharmacol Biol Psychiatry. 2007 ; 31: 1084-1088
5. Campos SB, Miranda DM, Souza BR, et al. Association study of tryptophan hydroxylase 2 gene polymorphisms in bipolar disorder patients with panic disorder comorbidity. Psychiatr Genet. 2011 ; 21: 106-111
6. Carrard A, Salzmann A, Malafosse A, et al. Increased DNA methylation status of the serotonin receptor 5HTR1A gene promoter in schizophrenia and bipolar disorder. J Affect Disord. 2011 ; 132: 450-453
7. Carson RE, Toczek MT, Lang LX, et al. Human functional imaging with the 5-HT1A ligand F-18-FCWAY. J Nucl Med. 2002 ; 43: 55
8. Carson RE, Wu Y, Lang L, et al. Brain uptake of the acid metabolites of F-18-labeled WAY 100635 analogs. J Cereb Blood Flow Metab. 2003 ; 23: 249-260
9. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 1991 ; 5: 219-229
10. Chen G, Yuan PX, Jiang YM, et al. Valproate robustly enhances AP-1 mediated gene expression. Brain Res Mol Brain Res. 1999 ; 64: 52-58
11. Cowen PJ, McCance SL, Ware CJ, et al. Lithium in tricyclic-resistant depression. Correlation of increased brain 5-HT function with clinical outcome. Br J Psychiatry. 1991 ; 159: 341-346
12. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. J Nucl Med. 1994 ; 35: 1398-1406
13. Drevets WC. Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol. 2001 ; 11: 240-249
14. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999 ; 46: 1375-1387
15. Drevets WC, Thase ME, Moses-Kolko EL, et al. Serotonin-1A receptor imaging in recurrent depression: Replication and literature review. Nucl Med Biol. 2007 ; 34: 865-877
16. Fairchild G, Leitch MM, Ingram CD. Acute and chronic effects of corticosterone on 5-HT1A receptor-mediated autoinhibition in the rat dorsal raphe nucleus. Neuropharmacology. 2003 ; 45: 925-934
17. First MB, Spitzer RL, Gibbon M, et al Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: New York State Psychaitric Institute, Biometrics Research ; 2002 :
18. Flugge G. Dynamics of central nervous 5-HT1A-receptors under psychosocial stress. J Neurosci. 1995 ; 15: 7132-7140
19. Giovacchini G, Toczek MT, Lang L, et al. 5-HT1A receptors are reduced in temporal lobe epilepsy after partial-volume correction.. J Nucl Med. 2005 ; 44: 1128-1135
20. Gray L, Scarr E, Dean B. Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. Psychiatry Res. 2006 ; 143: 111-120
21. Haddjeri N, Blier P, de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci. 1998 ; 18: 10150-10156
22. Hahn CG, Umapathy Wang HY, et al. Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res. 2005 ; 39: 355-363
23. Hesen W, Joels M. Modulation of 5HT1A responsiveness in CA1 pyramidal neurons by in vivo activation of corticosteroid receptors. J Neuroendocrinol. 1996 ; 8: 433-438
24. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007 ; 27: 1533-1539
25. Jovanovic H, Cerin A, Karlsson P, et al. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res. 2006 ; 148: 185-193
26. Jovanovic H, Karlsson P, Cerin A, et al. 5-HT(1A) receptor and 5-HTT binding during the menstrual cycle in healthy women examined with [(11)C] WAY100635 and [(11)C] MADAM PET. Psychiatry Res. 2009 ; 172: 31-37
27. Kishi T, Okochi T, Tsunoka T, et al. Serotonin 1A receptor gene, schizophrenia and bipolar disorder: An association study and meta-Analysis. Psychiatry Res. 2011 ; 185: 20-26
28. Kraus MR, Al-Taie O, Schafer A, et al. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology. 2007 ; 132: 1279-1286
29. Kusumi I, Koyama T, Yamashita I. Effect of mood stabilizing agents on agonist-induced calcium mobilization in human platelets. J Psychiatry Neurosci. 1994 ; 19: 222-225
30. Le Francois B, Czesak M, Steubl D, et al. Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology. 2008 ; 55: 977-985
31. Lemonde S, Turecki G, Bakish D, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003 ; 23: 8788-8799
32. Lenze EJ, Shardell M, Ferrell RE, et al. Association of serotonin-1A and 2A receptor promoter polymorphisms with depressive symptoms and functional recovery in elderly persons after hip fracture. J Affect Disord. 2008 ; 111: 61-66
33. Lesch KP, Mayer S, Disselkamp-Tietze J, et al. 5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry. 1990 ; 28: 620-628
34. Li Q, Holmes A, Ma L, et al. Medial hypothalamic 5-hydroxytryptamine (5-HT)1A receptors regulate neuroendocrine responses to stress and exploratory locomotor activity: Application of recombinant adenovirus containing 5-HT1A sequences. J Neurosci. 2004 ; 24: 10868-10877
35. Liman J, Ganesan S, Dohm CP, et al. Interaction of BAG1 and Hsp70 mediates neuroprotectivity and increases chaperone activity. Mol Cell Biol. 2005 ; 25: 3715-3725
36. Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry. 2004 ; 55: 225-233
37. Lopez JF, Chalmers DT, Little KY, et al. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry. 1998 ; 43: 547-573
38. McQuade R, Leitch MM, Gartside SE, et al. Effect of chronic lithium treatment on glucocorticoid and 5-HT1A receptor messenger RNA in hippocampal and dorsal raphe nucleus regions of the rat brain. J Psychopharmacol. 2004 ; 18: 496-501
39. Maeng S, Hunsberger JG, Pearson B, et al. BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci U S A. 2008 ; 105: 8766-8771
40. Maes M, Calabrese J, Jayathilake K, et al. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: Evidence for increased central serotonergic neurotransmission. Psychiatry Res. 1997 ; 71: 67-76
41. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001 ; 7: 541-547
42. Mannel M, Muller-Oerlinghausen B, Czernik A, et al. 5-HT brain function in affective disorder: d,l-Fenfluramine-induced hormone release and clinical outcome in long-term lithium/carbamazepine prophylaxis. J Affect Disord. 1997 ; 46: 101-113
43. Meijer OC, de Kloet ER. Corticosterone suppresses the expression of 5-HT1A receptor mRNA in rat dentate gyrus. Eur J Pharmacol. 1994 ; 266: 255-261
44. Meijer OC, de Kloet ER. A role for the mineralocorticoid receptor in a rapid and transient suppression of hippocampal 5-HT1A receptor mRNA by corticosterone. J Neuroendocrinol. 1995 ; 7: 653-657
45. Meijer OC, Van Oosten RV, De Kloet ER. Elevated basal trough levels of corticosterone suppress hippocampal 5-hydroxytryptamine(1A) receptor expression in adrenally intact rats: Implication for the pathogenesis of depression. Neuroscience. 1997 ; 80: 419-426
46. Mendelson SD, McEwen BS. Autoradiographic analyses of the effects of restraint-induced stress on 5-HT1A, 5-HT1C and 5-HT2 receptors in the dorsal hippocampus of male and female rats. Neuroendocrinology. 1991 ; 54: 454-461
47. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 ; 134: 382-389
48. Moses-Kolko EL, Price JC, Thase ME, et al. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [C-11]WAY-100635. Synapse. 2007 ; 61: 523-530
49. Muhlbauer HD, Muller-Oerlinghausen B. Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: Further evidence for a central serotonergic action of lithium in man. J Neural Transm. 1985 ; 61: 81-94
50. Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992 ; 12: 571-583
51. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001 ; 158: 906-912
52. Neumeister A, Bain E, Nugent AC, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. 2004 ; 24: 589-591
53. Nugent AC, Bain EE, Carlson PJ, et al. Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression.. Eur Neuropsychopharmacol. in press ;:
54. Parsey RV, Arango V, Olvet DM, et al. Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab. 2005 ; 25: 785-793
55. Price LH, Charney DS, Delgado PL, et al. Lithium and serotonin function: Implications for the serotonin hypothesis of depression. Psychopharmacology (Berl). 1990 ; 100: 3-12
56. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007 ; 356: 1711-1722
57. Sargent PA, Rabiner EA, Bhagwagar Z, et al. 5-HT(1A) receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-(11)C]WAY-100635. J Affect Disord. 2010 ; 123: 77-80
58. Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol. 2009 ; 88: 17-31
59. Scheuch K, Holtje M, Budde H, et al. Lithium modulates tryptophan hydroxylase 2 gene expression and serotonin release in primary cultures of serotonergic raphe neurons. Brain Res. 2010 ; 1307: 14-21
60. Schneikert J, Hubner S, Martin E, et al. A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of glucocorticoid receptor activity. J Cell Biol. 1999 ; 146: 929-940
61. Shiah IS, Yatham LN, Lam RW, et al. Effects of divalproex sodium on 5-HT1A receptor function in healthy human males: Hypothermic, hormonal, and behavioral responses to ipsapirone. Neuropsychopharmacology. 1997 ; 17: 382-390
62. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002 ; 17: 143-155
63. Sullivan GM, Ogden RT, Oquendo MA, et al. Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol Psychiatry. 2009 ; 66: 223-230
64. Szewczyk B, Albert PR, Burns AM, et al. Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. Int J Neuropsychopharmacol. 2009 ; 12: 155-168
65. Toczek MT, Carson RE, Lang L, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology. 2003 ; 60: 749-756
66. Treiser SL, Cascio CS, O'Donohue TL, et al. Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science. 1981 ; 213: 1529-1531
67. Watanabe Y, Sakai RR, McEwen BS, et al. Stress and antidepressant effects on hippocampal and cortical 5-HT1A and 5-HT2 receptors and transport sites for serotonin. Brain Res. 1993 ; 615: 87-94
68. Wei Q, Lu XY, Liu L, et al. Glucocorticoid receptor overexpression in forebrain: A mouse model of increased emotional lability. Proc Natl Acad Sci U S A. 2004 ; 101: 11851-11856
69. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry. 1978 ; 133: 429-435
70. Yuan PX, Chen G, Huang LD, et al. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Brain Res Mol Brain Res. 1998 ; 58: 225-230
71. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden markov random field model and the expectation maximization algorithm. IEEE Trans Med Imaging. 2001 ; 20: 45-57
72. Zhong P, Ciaranello RD. Transcriptional regulation of hippocampal 5-HT1a receptors by corticosteroid hormones. Brain Res Mol Brain Res. 1995 ; 29: 23-34
73. Zhou R, Gray NA, Yuan P, et al. The anti-Apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci. 2005 ; 25: 4493-4502